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Background: The human oxytocin receptor (hOXTR) is implicated in the etiology of autism spectrum disorders (ASDs)
and is a potential target for therapeutic intervention. Several studies have reported single-nucleotide polymorphisms
(SNPs) of the OXTR gene associated with ASDs. These SNPs, however, reside outside the protein-coding region. Not
much is known about genetic variations that cause amino acid substitutions that alter receptor functions.
Methods: Variations in the OXTR gene were analyzed in 132 ASD patients at Kanazawa University Hospital in Japan
and 248 unrelated healthy Japanese volunteers by re-sequencing and real-time polymerase chain reaction-based
genotyping. Functional changes in variant OXTRs were assessed by radioligand binding assay and measurements of
intracellular free calcium concentrations ([Ca2+]i) and inositol 1,4,5-trisphosphate (IP3) levels.
Results: Six subjects (4.5%) in the ASD group and two in the control group (0.8%) were identified as heterozygotes
carrying the R376G variation (rs35062132; c.1126C>G); one individual from the ASD group (0.8%) and three members of
the control group (1.2%) were found to be carrying R376C (c.1126C>T). The C/G genotype significantly correlated with
an increased risk of ASDs (odds ratio (OR) = 5.83; 95% confidence interval (CI) = 1.16 to 29.33; P = 0.024, Fisher’s exact test).
Consistently, the G allele showed a correlation with an increased likelihood of ASDs (OR = 5.73; 95% CI = 1.15 to 28.61;
P = 0.024, Fisher’s exact test). The frequencies of the C/T genotype and the T allele in the ASD and control groups did not
differ significantly. We also examined changes in agonist-induced cellular responses mediated by the variant receptors
hOXTR-376G and hOXTR-376C. OXT-induced receptor internalization and recycling were faster in hOXTR-376G-
expressing HEK-293 cells than in cells expressing hOXTR-376R or hOXTR-376C. In addition, the elevation in [Ca2+]i and
IP3 formation decreased in the cells expressing hOXTR-376G and hOXTR-376C tagged with enhanced green fluorescent
protein (EGFP), in comparison with the cells expressing the common-type hOXTR-376R tagged with EGFP.
Conclusions: These results suggest that the rare genetic variation rs35062132 might contribute to the pathogenesis of
ASDs, and could provide a molecular basis of individual differences in OXTR-mediated modulation of social behavior.
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Oxytocin (OXT) is a nonapeptide hormone primarily
produced by magnocellular neurons in the paraventricular
and supraoptic nuclei of the hypothalamus [1-6]. Oxytocin
is secreted into the systemic circulation via the hypothal-
amic-neurohypophyseal system and transported to exert
its peripheral effects, such as uterine contractions and
milk ejection [1-6]. Oxytocin is released into the brain
from dendrites [7] or centrally projected axonal terminals
[8], and it acts on various areas of the central nervous
system, modulating affiliative and social behaviors,
emotional states, and cognitive functions in many animal
species [1-6].
The actions of OXT are mediated by the OXT receptor
(OXTR), which belongs to the GTP-binding protein-
coupled receptor family [9]. It is well established that the
OXTR is coupled to heterotrimeric Gq/11 protein and
that it stimulates phospholipase Cβ (PLCβ), leading to
the production of inositol 1,4,5-trisphosphate (IP3) and
1,2-diacylglycerol (DAG) [9]. Inositol 1,4,5-trisphosphate
induces an increase in intracellular calcium concentration
([Ca2+]i) by triggering IP3 receptor-mediated Ca
2+ release
from intracellular stores, whereas DAG activates protein
kinase C (PKC), which phosphorylates downstream signaling
molecules [9]. Upon prolonged agonist stimulation, OXTR
undergoes desensitization and internalization through
phosphorylation by GPCR kinase 2 (GRK2) and subse-
quent interaction with β-arrestin 2 [9-13]. The internalized
OXTRs are then recycled to the cell surface via vesicles
containing small GTPases, Rab4 and Rab5 [13].
Previous studies have shown that impaired OXTR-
mediated signaling causes behavioral abnormalities [2,6,14].
Mice deficient in the OXTR gene show diminished social
discrimination, increased aggressive behavior, reduced
cognitive flexibility, and increased susceptibility to seizures
[15,16]. Using homozygous mutant mice lacking CD38, a
transmembrane protein with ADP-ribosyl cyclase activity,
we have shown that a decrease in the formation of cyclic
ADP-ribose (cADPR) results in dysfunction of Ca2+-in-
duced Ca2+ release for OXT secretion in hypothalamic
neurons. The reduction in cADPR levels also causes
marked defects in maternal nurturing and social behaviors
similar to those observed in OXT- and OXTR-knockout
mice [17,18]. We also demonstrated that ADP-ribosyl
cyclase activity increases after OXTR stimulation, regulating
OXT release in the hypothalamus and pituitary in adult
male mice [19].
In humans, OXTR has been implicated in the patho-
genesis of neuropsychiatric disorders and considered a
potential target for therapeutic intervention [20]. Gregory et
al. [21] have reported a heterozygous deletion of the OXTR
gene, located on chromosome 3p25, in a patient with
autism whose mother had a putative obsessive-compulsive
disorder. In addition, many studies have demonstratedthat single-nucleotide polymorphisms (SNPs) of the
OXTR gene are associated with autism spectrum disorders
(ASDs), social anxiety disorders, and schizophrenia
[22-29]. However, all SNPs reported so far reside outside
the protein-coding region, and their functional import-
ance is unclear. If allelic variations leading to amino acid
substitutions in the OXTR gene were associated with these
neuropsychiatric disorders, then such variations would
help to predict the etiological relevance based on protein
structure-function relationship and to introduce individu-
alized OXT-based therapy.
Therefore, we analyzed nucleotide variations in the
protein-coding regions of the human OXTR gene in ASD
patients and unrelated healthy controls. Furthermore, we
focused on a triallelic variation (rs35062132; c.1126C>
G/T; the nomenclature of variation recommended by the
Human Genome Variation Society [30]) and investigated
whether the amino acid substitution R376G/C causes any
changes in OXTR-mediated cellular responses.Methods
Participants
We recruited 132 ASD subjects (102 males, 30 females;
15.9 ± 0.7 years) from the outpatient psychiatry department
of the Kanazawa University Hospital. All subjects fulfilled
the DSM-IV criteria for pervasive developmental disorder.
The diagnoses were made by two experienced child
psychiatrists through interviews and clinical record
reviews as described previously [31], and the subjects
had no apparent physical anomalies. The two experienced
child psychiatrists independently confirmed the diagnosis
of ASD for all patients by semi-structured behavior obser-
vation and interviews with the subjects and their parents.
During each of these interviews with parents, which were
helpful in the evaluation of autism-specific behaviors and
symptoms, the examiners used one of the following
methods: the Asperger Syndrome Diagnostic Interview
[32], the Autism Diagnostic Interview-Revised (ADI-R)
[33], the Pervasive Developmental Disorders Autism
Society Japan Rating Scale [34], the Diagnostic Interview
for Social and Communication Disorders [35], or the
Tokyo Autistic Behavior Scale [36]. Based on these
evaluation methods, 97 patients were classified as
autistic disorder (autism), 10 as Asperger’s disorder,
and 25 as pervasive developmental disorder not other-
wise specified (PDD-NOS). The 248 controls (143
males, 105 females; 31.3 ± 0.6 years) were unrelated
healthy Japanese volunteers. All patients and controls
were Japanese with no non-Japanese parents or grand-
parents. This study was approved by the ethics
committees of Kanazawa University School of Medicine.
All examinations were performed after informed consent
according to the Declaration of Helsinki.
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Genomic DNA was extracted from venous blood samples
using the Wizard Genomic DNA Purification kit (Promega,
Madison, WI, USA), or from nails using the ISOHAIR
DNA extraction kit (Nippon Gene, Tokyo, Japan). DNA
fragments containing exons 3 and 4 of the hOXTR gene
were amplified by PCR in a 20-μl reaction mixture
containing 2.5 ng genomic DNA, 200 μM dNTPs, 200 nM
of each primer, 4 μl Ampdirect G/C (Shimadzu, Kyoto,
Japan), 4 μl Ampdirect-4 (Shimadzu), and 1 unit Ex Taq
DNA polymerase (Takara Shuzo, Otsu, Japan). The ampli-
fication procedure consisted of denaturation at 96°C for 1
min, followed by 35 cycles of 96°C for 30 s, 65°C for 1
min, and 72°C for 1 min. The primers used were FWD1
or FWD4 and REV1 for exon 3, and FWD5 and REV3 for
exon 4 (sequences are given in Table 1). After amplifica-
tion, PCR products were purified with the High Pure
PCR Cleanup Micro kit (Roche, Mannheim, Germany),
subjected to cycle sequencing reaction (BigDye version
1.1; Applied Biosystems, Foster City, CA, USA) according
to the manufacturer’s protocol, and analyzed on an ABI
PRISM 310 Genetic Analyzer (Applied Biosystems). The
primers used were FWD1–FWD5 and REV1–REV6
(Table 1).
Real-time PCR
Two primers, FWD8 and REV7 (Table 1), were designed
to amplify a 138-bp product encompassing rs35602132
at the mRNA position 1748 (g.8734707; c.1126). Three
custom-designed TaqMan minor groove binder (MGB)
probes were obtained from Applied Biosystems: 376G-
FAM and 376C-FAM targeted to the variant alleles, and
376R-VIC to the common allele (Table 1). PCR was
performed in 20-μl mixtures containing 10 μl TaqMan
universal master mix (Applied Biosystems), 200 nM of
each primer, 100 nM 376R-FAM, 100 nM 376G-VIC or
376C-VIC, and 10 ng of sample DNA. Thermocycling
was performed on the ViiA 7 Real-Time PCR System
(Applied Biosystems). The amplification was conducted
at 60°C for 30 s, 95°C for 5 min, and 40 cycles of 95°C
for 15 s and 60°C for 1 min. Data were analyzed with
SDS2.3 software (Applied Biosystems).
Site-directed mutagenesis
cDNAs encoding hOXTR variants at amino acid residue
376 were generated by site-directed mutagenesis as de-
scribed previously [37]. pCHOXTR [38] harboring
hOXTR-376R, a common-type receptor, was used as a
template for PCR; the primers used were R376G-FWD
and R376G-REV (Table 1) for the R376G substitution,
and R376C-FWD and R376C-REV (Table 1) for R376C.
The amplified products were treated with EX Taq DNA
polymerase (Takara Shuzo) at 72°C for 10 min and
cloned into a pCR2.1-TOPO vector (Invitrogen,Carlsbad, CA, USA) to yield pCHOXTR-376G and
pCHOXTR-376C. The cDNA inserts were verified by
nucleotide sequencing.
Construction of expression plasmids
The 1.4-kb EcoRI fragments from pCHOXTR [38],
pCHOXTR-376G, and pCHOXTR-376C were cloned
into the EcoRI site of the mammalian expression plasmid
pcDNA3.1 (+) (Invitrogen) to yield pcDNAHOXTR-
376R, pcDNAHOXTR-376G, and pcDNAHOXTR-376C,
respectively.
In some experiments, hOXTRs of the common type
and variants were fused to the enhanced green fluores-
cent protein (EGFP). Expression plasmids for these
fusion proteins were constructed essentially as described
previously [38]. In brief, the 1.4-kb EcoRI fragments
obtained from pCHOXTR [38], pcDNAHOXTR-376G,
and pcDNAHOXTR-376C were subjected to PCR using
primers EGFP-FWD and EGFP-REV (Table 1). The amp-
lified fragments were cleaved with PstI and BamHI. The
resulting 0.46-kb PstI (1334)/BamHI (primer) fragments
and the 0.78-kb BamHI (556)/PstI (1334) fragment
from pCHOXTR were ligated to BamHI/BglII-cleaved
pEGFP-N3 (Clontech) to yield pHOXTR-376R-EGFP,
pHOXTR-376G-EGFP, and pHOXT-R376C-EGFP. Restric-
tion endonucleasesites are identified by numbers (in
parentheses; in accordance with the data deposited in
GenBank under accession number NM_000916) indicating
the 5'-terminal nucleotide generated by cleavage.
Cell culture and transfection
Human embryonic kidney HEK-293 cells and COS-7
cells were maintained in DMEM supplemented with
10% FBS at 37°C in a humidified atmosphere of 95% air
and 5% CO2. NG108-15 neuroblastoma × glioma hybrid
cells were cultured as described previously [39]. Cells
were grown in culture dishes to 80 to 90% confluence and
transfected with expression plasmids using FuGENE HD
Transfection Reagent (Roche) following the manufacturer’s
instruction.
Radioligand binding assay
COS-7 cells transfected with pcDNAHOXTR-376R,
pcDNAHOXTR-376G, pcDNAHOXTR-376C, or pcDNA3.1
(+) were collected 48 h after transfection, and resuspended
in homogenization buffer (25 mM Tris, pH 7.4, 1 mM
EDTA, 250 mM sucrose). The cells were homogenized
and centrifuged at 1,500 g at 4°C for 10 min, to pellet
nuclei and intact cells. The resulting supernatants were
centrifuged at 40,000 g at 4°C for 30 min, and crude mem-
brane pellets were suspended in binding buffer containing
50 mM HEPES (pH 7.4), 5 mM MgCl2, 1 mM CaCl2, and
0.2% BSA. Protein concentration was determined by the
bicinchoninic acid assay (Pierce, Rockford, IL, USA) using
Table 1 Oligonucleotides used in this study
Nucleotide sequencing Real-time PCR-based genotyping Site-directed mutagenesis EGFP tagging
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PerkinElmer Life Sciences, Waltham, MA, USA) was
diluted in the binding buffer to concentrations of 0.05 to 4
nM. Specific binding assays were performed in 5-μg cell
membrane preparations incubated at room temperature
for 1 h with increasing concentrations of [3H]-OXT, in the
absence or presence of 200-fold excess of unlabeled OXT.
Binding reaction mixtures were filtered through a GF/C
glass fiber filter (Whatman, Maidstone, Kent, UK) and
washed three times with Wash Buffer (50 mM HEPES, pH
7.4, 500 mM NaCl, 0.1% BSA). Radioactivity associated
with membranes retained by glass filters was quantified in
a liquid scintillation counter (LSC-5100; Aloka, Tokyo,
Japan). Specific binding was calculated by subtracting
non-specific binding in the presence of 200-fold excess of
OXT at each radioligand concentration from total binding.
Affinity (Kd) and maximal binding capacity (Bmax) of
saturation binding were obtained from saturation isotherm
specific binding data by nonlinear regression curve analysis
using the standard equation for a rectangular hyperbola
fitted to one site with the GraphPad Prism 5 (GraphPad
Software Inc., San Diego, CA, USA). Competition binding
experiments were performed in duplicate by incubating
5 μg of cell membranes at room temperature for 1 h, in
the same medium with 1 nM [3H]-OXT and increasing
concentrations of unlabeled OXT (10−12 to 10−5 M).
Log IC50 values were derived from nonlinear least-squares
analysis using the GraphPad Prism 5 software (GraphPad
Software Inc.).
Measurement of receptor recycling
HEK-293 cells were plated on poly-D-ornithine-coated
glass coverslips and cultured overnight. After transfection
with pcDNAHOXTR-376R, pcDNAHOXTR-376G, or
pcDNAHOXTR-376C, the cells were incubated at 37°C in
serum-free DMEM for different times, in the absence or
presence of OXT (100 nM). Reactions were stopped by
removing the medium and fixing the cells with 4%
paraformaldehyde at room temperature for 10 min. The
cells were then blocked with PBS containing 1% BSA and
1.5% normal horse serum for 30 min, and incubated with
goat anti-OXTR antibody (N-19; 1:200; sc-8103, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) at 4°C
overnight. After washing in PBS, the cells were incubated
with donkey anti-goat IgG (H + L) antibody conjugated
with Alexa Fluor 488 (1:500; Invitrogen) combined with
4',6-diamidino-2-phenylindole (DAPI; 1 μg/ml; Dojindo,
Kumamoto, Japan). In some experiments, pSNAPf-ADRβ2
(New England Biolabs, Ipswich, MA, USA), an expression
plasmid for β2 adrenergic receptor fused to SNAPf, was
cotransfected into HEK-293 cells. The cells were labeled
with SNAP-Surface Alexa Fluor 488 (2 μM; New England
Biolabs), fixed with 4% paraformaldehyde, and reacted
with goat anti-OXTR antibody (N-19; 1:200; Santa Cruz)at 4°C overnight, followed by incubation with donkey anti-
goat IgG (H + L) antibody conjugated with Alexa Fluor
594 (1:500; Invitrogen); none of the solutions contained
any cell-permeabilizing reagents. Fluorescent images were
obtained using confocal laser scanning microscopes
(LSM5 Pascal; Carl Zeiss, Jena, Germany; FluoView
FV10i, Olympus). Data were analyzed using the FV10-
ASW software (Olympus).
[Ca2+]i measurement
We measured [Ca2+]i using the fluorescent Ca
2+ indicator
fura-2-acetoxymethyl ester (fura-2/AM). HEK-293 cells or
NG108-15 cells transfected with pHOXTR-376R-EGFP,
pHOXTR-376G-EGFP, or pHOXTR-376C-EGFP were
loaded with fura-2/AM to a final concentration of 3 μM
in complete medium and incubated at 37°C. After 30-min
loading, the cells were washed three times with HEPES-
buffered saline (HBS) solution (145 mM NaCl, 5 mM KCl,
1 mM MgCl2, 20 mM HEPES-NaOH, 2 mM CaCl2, 20
mM glucose, pH 7.4). Cells expressing EGFP-tagged
OXTRs were visualized at a wavelength of 488 nm before
OXT application. The fluorescence of the cells loaded with
fura-2/AM was then measured at 37°C, at the determined
sites, through a pinhole (10 to 20 μm in diameter). We
used alternating excitation wavelengths of 340 and 380
nm in a Ca2+ microspectrofluorometric system (OSP-3
Model; Olympus, Tokyo, Japan), as described previously
[39]. The Ca2+ emission was detected every 10 s for 5 min
after OXT application. The ratio of fluorescence at 340 nm
and 380 nm (F340/F380) was used to determine [Ca
2+]i. All
data were normalized to the baseline fluorescence (F0)
recorded 10 s before OXT addition, and given as F/F0.
IP3 accumulation assay
HEK-293 cells were plated at a density of approximately
5 × 104 per well in a 24-well plate, and transiently
transfected with pcDNAHOXTR-376R, pcDNAHOXTR-
376G or pcDNAHOXTR-376C, or pcDNA3.1(+). Before
treatment with OXT, the transfected cells were washed
and incubated in HBS containing 2 mM CaCl2, 10 mM
glucose, and 10 mM LiCl at 37°C for 10 min. After OXT
treatment, the reaction was terminated at designated
time points by the addition of 50 μl of 10% (w/v)
perchloric acid. The acid-soluble extract was neutralized
with 150 μl of 1.53 M KOH-75 nM HEPES, and
perchloric acid was precipitated on ice and removed by
a brief centrifugation. The IP3 aqueous extract was then
examined with an Inositol-1,4,5-triphosphate [3H]-Radio
Receptor Assay Kit (PerkinElmer Life Sciences).
Statistical analyses
Data obtained from genetic studies were analyzed using a
contingency table and the Fisher’s exact test (GraphPad
Prism 5; GraphPad Software Inc.). All data from the
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mean. Statistical significance was determined by the
Student’s t test or two-way analysis of variance (ANOVA)
using an interactive fitting program (GraphPad Prism 5;
GraphPad Software Inc.); P values smaller than 0.05 were
considered to be statistically significant.
Results
Genetic analysis
As the entire amino acid sequence of the hOXTR is
encoded by exons 3 and 4, as illustrated in Figure 1A,
we initially re-sequenced both exons for genetic variations.
Of 27 single-nucleotide variations listed in the NCI dbSNP
database, we detected minor alleles of rs4686302,
rs151257822, and rs35062132 in 59 ASD patients and 30
unrelated healthy Japanese volunteers (Figure 1A, Table 2).
As c.1126 G>C (rs35062132; R376G) was detected in two
ASD patients but not in controls (Table 2, Figure 1B), we
selected rs35062132 for further analysis.Figure 1 Triallelic variation rs35062132 in the human OXTR gene.
(A) Structure of the human OXTR gene and amino acid sequence of
the C-terminal portion of the human OXTR. White and black blocks
represent untranslated regions and protein-coding regions,
respectively, and red letters represent minor amino acid variations.
Indicated in the protein-coding region are rs4686302, rs151257822,
and rs35062132, in which allelic heterozygosity was detected in this
study. The region required for coupling to Gq isunderlined; potential
PKC phosphorylation sites are indicated by boxes, and Ser triplets are
double underlined. (B) Representative electrophoretograms of the
rs35062132 (c.1126C>G/T; R376G/C). Left, homozygote for the
common allele (376R/376R); middle, heterozygous carrier of c.1126C>G
(376R/376G); right, heterozygous carrier of c.1126C>T (376R/376C).
Arrows indicate the polymorphic position. Nucleotides and amino acids
for minor alleles are shown in red.We genotyped an additional 73 ASD patients and 218
healthy volunteers for rs35062132 variation using the
TaqMan-based real-time PCR method. In total, we
obtained data from 132 ASD patients and 248 controls.
Six individualsin the ASD group (4.5%) and two in the
control group (0.8%) were identified as heterozygotes
carrying the R376G variation (rs35062132; c.1126C>G).
One person in the ASD group (0.8%) and three in the
control group (1.2%) carried R376C (c.1126C>T; Table 3).
No homozygous carriers for the minor alleles were ob-
served. The χ2 goodness-of-fit test showed that the
genotype frequency distribution of rs35062132 did not
deviate from Hardy-Weinberg equilibrium in the patient
group (χ2 = 0.098, P = 0.99) or the control group (χ2 =
0.026, P = 1.00). The genotype and allele frequencies of
rs35062132 obtained from all participants are summa-
rized in Table 3. The C/G genotype was significantly
correlated with an increased risk of ASDs (odds ratio
(OR) = 5.83; 95% confidence interval (CI) = 1.16 to 29.3;
P = 0.024, Fisher’s exact test; Table 3). Consistently, the
G allele also showed a correlation with an increased like-
lihood of ASDs (OR = 5.73, 95% CI = 1.15 to 28.6;
P = 0.024, Fisher’s exact test; Table 3). The frequencies
of the C/T genotype and the T allele did not significantly
differ between the ASD and control groups (Table 3).
Radioligand binding properties of the common and
variant hOXTRs
To find out whether the amino acid changes at the resi-
due 376 affect the receptor functions, we compared
ligand-binding properties of the common and variant
hOXTRs. In saturation binding and Scatchard analysis
of 3[H]-OXT binding to membranes prepared from
COS-7 cells transfected with hOXTR-expression plasmids,
the variants hOXTR-376G and hOXTR-R376C, as well as
the common-type hOXTR-376R, exhibited single high-
affinity binding sites. Values of Kd were 0.90 ± 0.28, 1.1 ±
0.12, and 1.2 ± 0.19 nM (n = 15 in each group), and values
of Bmax were 3153 ± 531, 3202 ± 234, and 3120 ± 339
fmol/mg of protein (n = 15 in each group) for hOXTR-
376R, hOXTR-376G, and hOXTR-376C, respectively.
Competition binding experiments confirmed that the
variant and common receptors did not differ significantly:
values of IC50 were 1.05 ± 0.47, 0.49 ± 0.23, and 0.71 ±
0.30 nM (n = 15 in each group) for hOXTR-376R,
hOXTR-376G, and hOXTR-376C, respectively. These data
indicate that both variations have no or little effect on
OXT binding.
Agonist-induced receptor internalization and recycling in
HEK-293 cells
We then examined the agonist-induced internalization
and recycling of hOXTRs in HEK-293 cells, which have
been most extensively used for investigation of GPCR
Table 2 Frequency of non-synonymous single-nucleotide variations in the OXTR gene detected by re-sequencing
dbSNP-IDa mRNAb Allele Amino acid Amino acid Number of cases
position position residue ASD (n= 59) Control (n= 30)
rs237908 19 T/G 7 S/A T/T (0) T/G (0) G/G (59) T/T (0) T/G (0) G/G (30)
rs237907 40 T/G 14 S/A T/T (0) T/G (0) G/G (59) T/T (0) T/G (0) G/G (30)
rs237906 46 T/G 16 S/A T/T (0) T/G (0) G/G (59) T/T (0) T/G (0) G/G (30)
rs189386 64 T/G 22 W/G T/T (0) T/G (0) G/G (59) T/T (0) T/G (0) G/G (30)
rs113718500 65 C/G 22 A/G C/C (0) C/G (0) G/G (59) C/C (0) C/G (0) G/G (30)
rs237903 86 T/C 29 V/A T/T (0) T/C (0) C/C (59) T/T (0) T/C (0) C/C (30)
rs171114 188 G/C 63 G/A G/G (0) G/C (0) C/C (59) G/G (0) G/C (0) C/C (30)
rs143644523 220 T/C 74 F/L T/T (0) T/C (0) C/C (59) T/T (0) T/C (0) C/C (30)
rs138770371 316 G/T 106 D/Y G/G (0) G/T (0) T/T (59) G/G (0) G/T (0) T/T (30)
rs115324487 515 C/T 172 A/V C/C (0) C/T (0) T/T (59) C/C (0) C/T (0) T/T (30)
rs150746704 616 G/C 206 V/L G/G (0) G/C (0) C/C (59) G/G (0) G/C (0) C/C (30)
rs4686302 652 A/G 218 T/A A/A (3) A/G(12) G/G (34) A/A (1) A/G(14) G/G (15)
rs143908202 661 A/G 221 S/G A/A (0) A/G (0) G/G (59) A/A (0) A/G (0) G/G (30)
rs145921539 684 T/G 228 C/W T/T (0) T/G (0) G/G (59) T/T (0) T/G (0) G/G (30)
rs184175311 700 G/A 234 E/K G/G (0) G/A (0) A/A (59) G/G (0) G/A (0) A/A (30)
rs61740241 712 A/G 238 T/A A/A (0) A/G (0) G/G (59) A/A (0) A/G (0) G/G (30)
rs151141371 755 C/G 252 A/G C/C (0) C/G (0) G/G (59) C/C (0) C/G (0) G/G (30)
rs139854982 760 T/C 254 C/R T/T (0) T/C (0) C/C (59) T/T (0) T/C (0) C/C (30)
rs144366756 764 G/T 255 G/V G/G (0) G/T (0) T/T (59) G/G (0) G/T (0) T/T (30)
rs237901 818 T/C 273 M/T T/T (0) T/C (0) C/C (59) T/T (0) T/C (0) C/C (30)
rs144814761 841 A/G 281 M/V A/A (0) A/G (0) G/G (59) A/A (0) A/G (0) G/G (30)
rs140488139 963 A/C 321 K/N A/A (0) A/C (0) C/C (59) A/A (0) A/C (0) C/C (30)
rs151257822 1001 A/G 334 D/G A/A (0) A/G (0) G/G (59) A/A (0) A/G (1) G/G (29)
rs143927655 1015 A/G 339 K/E A/A (0) A/G (0) G/G (59) A/A (0) A/G (0) G/G (30)
rs148899442 1100 G/A 367 S/N G/G (0) G/A (0) A/A (59) G/G (0) G/A (0) A/A (30)
rs144289031 1121 A/G 374 N/S A/A (0) A/G (0) G/G (59) A/A (0) A/G (0) G/G (30)
rs35062132 1126 G/C 376 G/R G/G (0) G/C (2) C/C (57) G/G (0) G/C (0) C/C (29)
rs35062132 1126 T/C 376 C/R T/T (0) T/C (0) C/C (57) T/T (0) T/C (1) C/C (29)
aIDs are from dbSNP of the National Center for Biotechnology Information [40]. Bold IDs indicate the presence of allelic heterozygosity. bA of the ATG of the initial
methionine is denoted nucleotide +1.
Ma et al. Molecular Autism 2013, 4:22 Page 7 of 14
http://www.molecularautism.com/content/4/1/22internalization and trafficking. HEK-293 cells transfected
with an expression plasmid for hOXTR-376R, hOXTR-
376G, or hOXTR-376C were stimulated with 100 nM
OXT for 5, 10, 15, 30, 45, 60, 90, and 120 min. At each
time point, the cells were fixed and stained with antibody
pecific for the amino (N)-terminus, located extracellularly,
of the OXTR under impermeable conditions. The specifi-
city of the staining was confirmed by the comparison with
the staining of mock-transfected and non-transfected
HEK-293 cells (Additional file 1: Figure S1).
Immunoreactivity for hOXTRs was visualized by con-
focal laser scanning microscopy (Figure 2A). Immuno-
fluorescence was measured and expressed as a percentage
of the intensity for receptors remaining at the cell surface.
Cell-surface intensity for hOXTR-376R reached the lowest
value of 43.9 ± 2.3% (n = 30) after 60 min, and then
gradually increased to 77.1 ± 8.7% (n = 29) of theprestimulatory level at 120 min. OXT-induced internal-
ization in the cells expressing hOXTR-376C were very
similar to that for hOXTR-376R: the surface intensity
decreased to 45.1 ± 3.3% (n = 30) at 60 min, and then
elevated to 79.4 ± 18.1% (n = 8) at 120 min. In contrast,
the surface intensity of hOXTR-376G showed a signifi-
cantly faster decrease than that for hOXTR-376R at 5
min after OXT application (62.5 ± 4.7% (n = 25) for
hOXTR-376G, 78.7 ± 6.7% (n = 15) for hOXTR-376R;
P <0.05; Student’s t test). In addition, hOXTR-376G
showed significantly higher levels of surface intensities
from 30 min to 120 min after OXTapplication (Figure 2B).
The values at 30, 45, 60, and 120 min were 59.6 ±
2.7 (n = 30, P <0.05; Student’s t test), 61.4 ± 3.0 (n = 30,
P <0.05; Student’s t test), 67.7 ± 3.7 (n = 30, P <0.01; Stu-
dent’s t test), and 96.1 ± 6.6% (n = 23, P <0.05; Student’s
t test) for hOXTR-376G, compared with 52.0 ± 2.5 (n = 30),
Figure 2 Agonist-induced internalization and recycling of common an
transfected with expression plasmids for the common-type hOXTR-376R an
using antibody against the N-terminus of hOXTR (Alexa Fluor 488, green) a
laser scanning microscopy at the indicated time points after the addition o
quantified and expressed as the percentage of receptors remaining at the
cells from five cultures). Statistical significance was evaluated by the Studen
Table 3 Comparison of the genotype and allele










C/C 125 (94.7%) 243 (98.0%) Referent
C/G 6 (4.5%) 2 (0.8%) 5.83 (1.16,29.3) 0.024





C 257 (97.3%) 491 (99.0%) Referent
G 6 (2.3%) 2 (0.4%) 5.73 (1.15,28.6) 0.024
T 1 (0.4%) 3 (0.6%) 0.64 (0.07,6.16) 1.00
CI, confidence interval. P values obtained by Fisher’s exact test are given.
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http://www.molecularautism.com/content/4/1/2251.1 ± 3.1 (n = 30), 43.9 ± 2.3 (n = 30), and 77.1 ± 8.7%
(n = 29) for hOXTR-376R, respectively (Figure 2B). The
majority of the hOXTR-immunoreactivity was colocalized
with fluorescence for SNAPf-tagged β2-adrenergic receptor
as a plasma membrane marker (>84%; Additional file 2:
Figure S2). These data demonstrate that, upon agonist
stimulation, hOXTR-376G is internalized into the cyto-
plasm and recycled to the plasma membrane more rapidly
than hOXTR-376R and hOXTR-376C.
Agonist-induced Ca2+ mobilization in HEK-293 cells and
NG108-15 neuronal cells
To examine whether the amino acid substitutions altered
the coupling to intracellular signaling system, we measured
OXT-induced Ca2+ mobilization. Both HEK-293 cells and
NG108-15 neuroblastoma × glioma hybrid cells were
transfected with an expression plasmid for EGFP-tagged
hOXTR-376R, hOXTR-R376G, or hOXTR-376C. Before
OXT stimulation, EGFP fluorescence was homogenously
distributed in both HEK-293 cells and NG108-15 neuronal
cells expressing hOXTR-376R-EGFP, hOXTR-376G-EGFP,
and hOXTR-376C-EGFP, as previously reported [13]d variant hOXTRs. (A) Fluorescent images of HEK-293 cells
d variants hOXTR-376G and hOXTR-R376C. Cells were double-labeled
nd a nuclear marker (DAPI, blue). Images were obtained by confocal
f OXT (100 nM). (B) Fluorescence intensities for hOXTRs were
cell surface. Data are mean ± standard error of the mean (n = 15 to 30
t’s t test (* P <0.05, **P <0.01; compared with hOXTR-376R).
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http://www.molecularautism.com/content/4/1/22(Figure 3A,B). After loading these cells with Ca2+-sensitive
fluorescent dye fura-2/AM, the effect of the amino acid
variations on OXT-induced increase in [Ca2+]i was
analyzed using a dual-wavelength (340 and 380 nm) fluor-
escence spectrophotometer.
The addition of 100 nM OXT to HEK-293 cells express-
ing hOXTR-376R-EGFP induced a rapid initial increase of
[Ca2+]i; the levels reached 223 ± 19.6% (n = 24) of the
prestimulatory level and then returned to the basal level
within 3 min (Figure 3C,E). In contrast, both hOXTR-
376G-EGFP- and hOXTR-376C-EGFP-expressing HEK-
293 cells exhibited significantly smaller initial peaks:
the maximum [Ca2+]i was 142 ± 13.2% (n = 24) and
159 ± 3.8% (n = 31) for hOXTR-376G-EGFP and hOXTR-
376C-EGFP, respectively (Figure 3C,E). Mock-transfected
control cells did not show Ca2+ mobilization at all
(Figure 3C,E).
The same tendency was observed in NG108-15 neur-
onal cells. [Ca2+]i initially increased to relatively low levels
compared with those in HEK-293 cells. The maximum
[Ca2+]i levels at the initial peak in hOXTR-376G-EGFP-
and hOXTR-376C-EGFP-expressing NG108-15 cells were
137 ± 5.1% (n = 28) and 128 ± 2.0% (n = 18), respectively,
significantly lower than those in hOXTR-376R-EGFP-
expressing cells, which reached 161 ± 5.1% (n = 24;
Figure 3D,F).Agonist dose-dependent Ca2+ mobilization
We further examined the OXT dose-dependence during
the increase in [Ca2+]i in HEK-293 cells expressing the
common and variant hOXTRs. OXT concentrations
ranging from 10−11 to 10−6 M were tested. When the
OXT concentration was lower than 10−10 M, no differ-
ences in the initial [Ca2+]i rise were observed in the cells
expressing hOXTR-376R-EGFP, hOXTR-376G-EGFP,
and hOXTR-376C-EGFP (Figure 4A,B). In the cells
expressing hOXTR-376R-EGFP, the maximum initial
increase in [Ca2+]i was at 10
−7 M OXT (Figure 4A,B).
In HEK293 cells expressing hOXTR-376G-EGFP, the
maximal [Ca2+]i increase was obtained at 10
−8 M OXT
(158 ± 5.2% (n = 24); Figure 4A,B). OXT at 10−7 and 10−6
M resulted in significantly smaller [Ca2+]i increases
compared with those for hOXTR-376R-EGFP, with
initial peak values being 142 ± 13.2% (n = 24) and 129 ±
7.2% (n = 16), respectively.
In HEK-293 cells expressing hOXTR-376C-EGFP,
the maximal [Ca2+]i increase was obtained at 10
−7 M
(159 ± 3.8% (n = 31); Figure 4A,B). At concentrations
higher than 10−9 M, the OXT-induced increase in [Ca2+]i
was significantly reduced (Figure 4A,B). These data
suggested that the rs35062132 variations (R376G/C)
might alter the OXTR-mediated changes in the intracellular
calcium concentrations.Agonist-induced IP3 accumulation in HEK-293 cells
IP3 is known to mediate OXT-induced increase in [Ca
2+]i
levels. Therefore, we investigated whether the amino acid
substitutions could affect IP3 production. As shown in
Figure 5, in HEK-293 cells expressing hOXTR-376R-EGFP,
100 nM OXT elicited an increase in IP3 level within initial
10 s; this increase was maintained for 30 s and the level
returned to its basal value after 3 min. Mock-transfected
cells did not show any changes. The cells expressing
hOXTR-376G-EGFP and hOXTR-376C-EGFP also stimu-
lated IP3 production. During the whole period of 3 min
after OXT application, IP3 production in cells expressing
hOXTR-376G-EGFP was not statistically different com-
pared with hOXTR-376R-EGFP (P = 0.1705, F(1, 217) =
1.89; two-way ANOVA), whereas cells expressing
hOXTR-376C-EGFP showed significantly smaller IP3
production (P = 0.003, F(1, 210) = 9.01; two-way ANOVA).
During the initial 5 to 30 s after OXT application, a slight
but significant drop from the maximum IP3 levels was
observed in these cells, compared with the values for
hOXTR-376R-EGFP (P = 0.0210, F(1, 107) = 5.49
for hOXTR-376G-EGFP; P = 0.0209, F(1, 103) = 5.5 for
hOXTR-376C-EGFP; two-way ANOVA).
Discussion
The main findings of this study are as follows. (i) Triallelic
non-synonymous variation (rs35062132, c.1126C>G/T;
R376G/C) is observed in both ASD patients and healthy
controls in a Japanese population; the frequencies of the G
allele are significantly higher in the ASD patients than in
healthy controls. (ii) In HEK-293 cells expressing hOXTR-
376G, the agonist-induced internalization and recycling of
the OXTR are faster than that in the cells expressing
hOXTR-376C or hOXTR-376R. (iii) In both HEK-293
cells and NG108-15 neuronal cells, the agonist-induced
increase in [Ca2+]i mediated by hOXTR-376G-EGFP or
hOXTR-376C-EGFP is smaller than the increase associ-
ated with hOXTR-376R-EGFP. These results provide new
insights into the genetic architecture and therapeutic as-
pects of ASDs.
The present study is unique in associating non-
synonymous allelic variations of the OXTR gene with
ASDs. These variations at rs35062132 have not been
reported in other disorders. To date, several studies
have found ASD-associated SNPs in the OXTR gene,
which reside in introns (rs4564970 [41], rs237897 [25],
rs53576 [23,24], rs2254298 [23-25], rs2268493 [42],
rs7632287 [42], rs11720238 [41]), 3'-untranslated region
(rs1042778) [42], and intergenic regions (rs7632287 and
rs11720238) [41]. The functional consequences of these
SNPs remain unclear. Importantly, all minor alleles of these
SNPs have a frequency more than 5%, and thus can be
classified as common variations. In contrast, the frequencies
of the G and T alleles of rs35062132 are 0.4% and 0.6%,
Figure 3 Agonist-induced Ca2+ mobilization. (A,B) HEK-293 cells and NG108-15 neuronal cells were transfected with expression plasmids for
EGFP-tagged hOXTR-376R (common type) and visualized by fluorescence microscopy. Scale bar, 10 μm. (C,D) Images of fluorescence changes in
HEK-293 cells (C) and NG108-15 cells (D) expressing hOXTR-376R-EGFP (top), hOXTR-376G-EGFP (middle), and hOXTR-376C (bottom) are shown
before and after treatment with 100 nM OXT. The ratio of fluorescence intensities detected at 340 and 380 nm was used to determine [Ca2+]i.
Emission ratio values ((F/F0) were pseudo-colored to represent calcium concentrations according to the scale bar on the right. Black arrows
indicate application with 100 nM OXT; and white arrows show large [Ca2+]i changes in the cells after stimulation. Insets show larger images of the
cells indicated by arrows. Scale bar, 100 μm. (E,F) Average time courses of changes in [Ca2+]i elicited with 100 nM OXT were measured in HEK-
293 cells (E) and NG108-15 neuronal cells (F) expressing hOXTR-376R-EGFP, hOXTR-376G-EGFP, or hOXTR-376C-EGFP and in mock-transfected
cells. Values are mean ± standard error of the mean (n = 24 to 30 cells from three or four independent cultures; six to ten cells were analyzed in
each culture). Statistical significance was evaluated by the Student’s t test (* P <0.05, **P <0.01; compared with hOXTR-376R-EGFP).
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rized as rare [43-45]. Therefore, most previous studies favor
the common disease–common variant model, in which
most of the risk is caused by common genetic variations
(>5% allele frequency), each allele conferring a slight risk
[43-47]. By contrast, our results support the common
disease–rare variant model, in which the risk is mostly
attributable to rare variations (<5% allele frequency), each
variant conferring a moderate but readily detectable
increase in the relative risk [43-47]. In agreement with
this model, we observed that the minor alleles clearlyaffected OXT-induced cellular responses. Future studies
will be conducted to test whether behavioral changes
caused by these variations are moderate and reasonably
deleterious. Also it will be interesting to examine whether
the rs35062132 variations cosegregate with the risk alleles
in the non-coding region [22-24,41,42].
The limitation of this study is that sample size is not
sufficient to analyze the rare variant alleles at rs35062132.
Future studies with larger sample size or family-based
association testing are necessary to conclude that the G
allele of the rs35062132 is a genetic risk factor for ASDs.
Figure 5 Agonist-induced IP3 accumulation. Average time
courses of changes in IP3 accumulation elicited with 100 nM OXT;
IP3 levels were measured in HEK293 cells expressing hOXTR-376R-
EGFP, hOXTR-376G-EGFP, and hOXTR-376C-EGFP. Data are expressed
as mean ± standard error of the mean (n = 13 to 15 cultures from
five independent experiments). During the initial 5 to 30 s after OXT
application, a significant drop from the maximum IP3 levels was
observed in these cells (P = 0.0210, F(1, 107) = 5.49 for hOXTR-376G
-EGFP; P = 0.0209, F(1, 103) = 5.5 for hOXTR-376C-EGFP; compared
with the values for hOXTR-376R-EGFP; two-way ANOVA).
Figure 4 Agonist dose-dependent Ca2+ mobilization. (A) The changes in [Ca2+]i induced by various concentrations of OXT were measured in
HEK-293 cells expressing hOXTR-376R-EGFP, hOXTR-376G-EGFP, or hOXTR-376C-EGFP. (B) Relationship between OXT concentrations and [Ca2+]i at the
initial peak. Cells were infused with the indicated concentration of OXT. Each plot shows a percentage of [Ca2+]i at the initial peak after treatment with
OXT. Data are mean ± standard error of the mean (n = 8 to 30 cells from three or four independent cultures; two to eight cells were analyzed in each
culture). Statistical significance was evaluated by the Student’s t test (* P <0.05, **P <0.01; compared with hOXTR-376R-EGFP).
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ent populations with various ethnic backgrounds.
The amino acid variation R376G/C is located in the
intracellular carboxy (C)-terminal tail of the receptor pro-
tein, which is critical for desensitization, internalization,
and recycling of the OXTR, as in many other GPCRs
[9-13]. Arg376 is associated with two structural components
involved in these processes: (i) Arg376 is a part of a PKC
consensus motif (Ser374-His375-Arg376; Figure 1A), which is
thought to interact with PKC after OXT stimulation [10];
and (ii) Arg376 is in conjunction with one of the two Ser
triplets in the C-terminus (Figure 1A) that are primary
sites of agonist-induced phosphorylation and β-arrestin-2
binding [11]. When either one of the two Ser triplets was
mutated to alanine residues, the stability of the β-arrestin
-2-OXTR complex was altered, and the ability of β-
arrestin-2 to internalize with the receptor was elimi-
nated [11]. In the vasopressin receptor V2, which is
highly homologous to OXTR in structure, the equiva-
lent Ser triplets function as a retention motif. GRK
phosphorylation of these Ser residues promotes the
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followed by cotrafficking and colocalization of the com-
plexes to endocytotic vesicles and slow recycling to the cell
surface [48]. Therefore, it is suggested that the R376G
substitution in the OXTR might suppress the phosphoryl-
ation of Ser residues in the Ser triplets or reduce the sta-
bility of β-arrestin binding to the triplets, resulting in
faster receptor recycling.
We demonstrated that, both in HEK-293 cells and in
NG108-15 neuronal cells, agonist-induced [Ca2+]i elevation
mediated by variant receptors, hOXTR-376G-EGFP and
hOXTR-376C-EGFP, is smaller than that by the common
receptor hOXTR-376R-EGFP. Despite the marked reduc-
tion in the peak [Ca2+]i, the decrease in IP3 levels was
slight. Provided that Arg376 is not located in the known
site for Gq binding (Figure 1A) [49], the Gq/11/PLCβ/IP3-
independent, unidentified signaling pathway for [Ca2+]i
elevation might be affected by the R376G/C substitution.
Ca2+ signaling pathways in neurons have been impli-
cated in the pathogenesis of ASDs [50]. However, the
involvement of OXTR-mediated, PLC/IP3-dependent
Ca2+ signaling in ASDs is still largely unknown. Recently,
Ninan [51] has demonstrated that U73122, a PLC inhibitor,
reduced OXT-induced suppression of glutamatergic
synaptic transmission in pyramidal neurons of the medial
prefrontal cortex, possibly by inhibiting PLC-dependent
increase in postsynaptic calcium. Given that this process
is critical for the OXT effects on social cognition, it is
conceivable that the OXTR variations may serve as a risk
factor for ASDs.
We have previously demonstrated that cADPR, which
may act as an intracellular second messenger downstream
of the OXTR, activates Ca2+ release from intracellular
stores through the ryanodine receptor Ca2+ release chan-
nel. cADPR also initiates Ca2+ influx through melastatin-
related transient receptor potential 2 (TRPM2) channels
[38]. Our previous SNP analysis has suggested that R140W
substitution of CD38 protein, a regulator of ryanodine
receptor-mediated Ca2+-induced Ca2+ release for OXT
secretion [17], could be a potential risk factor for a subset
of Japanese ASD patients [31]. Although this study shares
a part of the ASD patients with our previous analysis [31],
the 140W allele of CD38 has not been found in the
patients carrying the OXTR-376G or OXTR-376C until
now (unpublished data). It is therefore conceivable that the
underlying signaling process affected by the R376G/C
substitution is independent of the CD38-mediated OXT
release from hypothalamic neurons [17].
Besides their relevance to the etiology of ASDs, the results
presented here might contribute to the development of new
pharmacological treatments. Genetic polymorphisms of
many drug targets predict responsiveness to drugs [52,53].
It is likely that the alteration in the cellular functions
mediated by the variant OXTRs could cause someindividual differences in both behavioral and non-
behavioral responses to OXT. Although no side effects
specific to intranasal OXT administration have been
reported [54], new clinical information regarding func-
tional OXTR variants will be helpful in the determination
of individual administration protocols to maximize thera-
peutic benefit with least adverse effects.
Conclusions
Our analysis of the genetic variation rs35062132 in the
human OXTR gene may be important for both etiological
and therapeutic aspects of ASDs. However, the results
reported here should be reproduced in an independent
population. Further studies with a larger sample size using
subjects of different ethnicities are required to confirm that
the G allele of the rs35062132 is a genetic risk factor for
ASDs. Identifying rare functional variants of the OXTR will
shed new light on the genetic architecture of ASDs and
allow personalized pharmacological intervention using
OXT.
Additional files
Additional file 1: Figure S1. Antibody validation. Fluorescent images of
HEK-293 cells transfected with expression plasmids for the common-type
hOXTR-376R (top, left) and variants hOXTR-376G (top, middle) and hOXTR-
376C (top, right). Images of HEK-293 cells transfected with an empty vector
(Mock) and non-transected cells (−). Cells were stained with anti-hOXTR
antibody and visualized with Alexa Fluor 488-conjugated secondary
antibody (green). DAPI was used to stain cell nuclei (blue). Note that
hOXTR-immunoreactivity is detected in cells transfected with expression
plasmids for the common and variant hOXTRs but not in mock- and non-
transfected cells. hOXTR-immunoreactive cells were detected in 11.8% (177/
1500 DAPI-positive cells in total of eight different fields), 15.5% (188/1210 in
total of eight different fields), 16.6% (224/1353 in total of eight different
fields), 0% (0/789 in total of four different fields), and 0% (0/748 in total of
four different fields) in hOXTR-376R-, hOXTR-376G-, hOXTR-376C-, mock-,
and non-transfected cells, respectively. Scale bar, 20 μm.
Additional file 2: Figure S2. Co-staining of hOXTRs with β2-adrenergic
receptor as a cell-surface marker. (A) Fluorescent images of HEK-293 cells
transfected with an expression plasmid for hOXTR-376R (left), hOXTR-376G
(middle), or hOXTR-376C (right), together with that for the plasma membrane
marker SNAPf-tagged β2 adrenergic receptor. Cells were stained with anti-
hOXTR antibody and visualized with Alexa Fluor 594-conjugated secondary
antibody (hOXTR, red). SNAPf-tagged β2 adrenergic receptor was labeled
with SNAP-Surface Alexa Fluor 488 (SNAPf-ADRβ2, green). DAPI was used to
stain cell nuclei (DAPI, blue). Note that hOXTR-immunoreactivity is mostly
overlapped with fluorescence for SNAPf-tagged β2 adrenergic receptor
(Merge, yellow). Scale bar, 10 μm. (B) OXTR-immunoreactivity overlapped
with SNAPf-tagged β2 adrenergic receptor. Data are mean ± standard error
of the mean. The overlapping at 0, 30, 60 min after OXT application (100 nM)
was estimated to be 86.0 ± 1.1% (n = 20), 83.1 ± 1.5% (n = 18), and 85.5 ±
1.0% at 60 min (n = 20), respectively, for hOXTR-376R; 86.1 ± 1.0% (n = 23),
84.9 ± 1.6% (n = 13), 84.6 ± 1.4% (n = 20), respectively, for hOXTR-376G; and
85.2 ± 1.2% (n = 32), 84.9 ± 1.8% (n = 16), and 84.1 ± 2.2% (n = 19),
respectively, for hOXTR-376C.
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